Iridium Announces Commercial Availability of Iridium PNT ASIC, Bringing Resilient GNSS Protection to Devices Worldwide
Ultra-compact chip delivers trusted positioning, navigation, and timing resilience amid rising spoofing and jamming threats MCLEAN, Va., July 14, 2026 /PRNewswire/ -- Iridium Communications Inc. (Nasdaq: IRDM), a leading provider of global voice, data, and positioning, navigation, and timing (PNT) satellite services, today announced the commercial availability of the Iridium PNT ASIC,...
VARON Expands Pet Oxygen Solutions with New Portable Oxygen Bundle and Pet Oxygen Mask
LOS ANGELES, July 14, 2026 /PRNewswire/ -- As more pet owners look for ways to support their pets' comfort and breathing needs beyond the veterinary clinic, VARON continues to expand its pet oxygen product line with the launch of a new portable pet oxygen bundle and pet oxygen mask. Building on its experience in portable and home oxygen concentrator...
Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer
HONG KONG, July 14, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen for the perioperative treatment of locally advanced, resectable HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. Cadonilimab...
STATEMENT FROM THE RIGMORA BIOTECH INVESTORS
MONACO, July 14, 2026 /PRNewswire/ -- The Rigmora Biotech Investors welcome the order issued July 10th 2026 by Hon. Justice Jalil Asif KC of the Grand Court of the Cayman Islands. Following the hearing on July 1, the court determined that control of ATP Life Sciences Ventures L.P. ("the Fund") should be taken away from the current General Partner,...
Converging at BIO, ACROBiosystems Connects Emerging Innovation Assets with Global Strategic Opportunities
SAN DIEGO, July 14, 2026 /PRNewswire/ -- Ahead of the BIO International Convention, BIOSeedin Summer Innovation Partnering Summit was successfully held at Wyndham San Diego Bayside, California. Hosted by bioSeedin, the summit's discussion topics were about early-stage innovation assets, late-stage clinical pipelines, business development strategies, M&A trends, multinational collaboration models, and global licensing transactions. ACROBiosystems participated as a key...
HKEY-AI-NAM-Bridge™ 1.0: HKeyBio Connects AI, NAMs and In Vivo Evidence
HKEY-AI-NAM-Bridge™ 1.0 connects AI predictions, new approach methodologies and in vivo evidence for more targeted preclinical study design BOSTON and SUZHOU, China, July 13, 2026 /PRNewswire/ -- HKeyBio has established HKEY-AI-NAM-Bridge™ 1.0, its AI and New Approach Methodologies (NAMs) In Vivo Evidence Bridging Package. The service helps autoimmune and allergy drug-development teams identify evidence gaps and design more...
IMG Opens Applications for 2026 Fall Semester ‘Student Journey Scholarship’
INDIANAPOLIS, July 13, 2026 /PRNewswire/ -- IMG (International Medical Group) is now accepting applications for its Student Journey Scholarship, a program designed to help international students fund their studies at a U.S. college or university. Entries for the 2026 Fall semester will be accepted July 13-October 4, 2026, and one student...
Servier completes the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business
Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs. SURESNES, France, July 13, 2026 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise...
Delonix Bioworks Announces First Participant Dosed in Phase 1 Clinical Trial of Next-Generation MenB OMV Vaccine DX-104 in China
SHANGHAI, July 13, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company pioneering genetically engineered bacterial vaccines, today announced that the first participant has been dosed in its Phase 1 clinical trial of DX-104 in China. DX-104 is an innovative Group B meningococcal (MenB) vaccine candidate developed using the company's proprietary OMV Plus® platform. This milestone marks a...
POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement
GUANGZHOU, China, July 13, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today announced that on July 10, 2026, the Company received a letter (the "Compliance Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance...
